A hidden structure inside the cell is rewriting how scientists understand leukemia. Beneath the microscope, what looked like ...
Q25 – – $32.0 million Revuforj® (revumenib) net revenue; total Revuforj prescriptions in 3Q25 increased 25% over 2Q25, highlighting strong demand – – $45.8 million Niktimvo™ (axatilimab-csfr) net ...
Incyte (Nasdaq:INCY) today announced that data from key programs in its oncology portfolio will be presented in both oral and poster sessions at the 2025 American Society of Hematology (ASH) Annual ...
Completed enrollment in soquelitinib atopic dermatitis Phase 1 trial extension cohort 4 (200 mg BID dose with 8-week treatment period) with data announcement anticipated in January ...
Study reshapes view of how a common leukemia begins and could point to new therapeutic strategies targeting a common weakness.
A hidden structure inside the cell is rewriting how scientists understand leukemia. Beneath the microscope, what looked like disorder turned out to ...
A hidden structure inside the cell is rewriting how scientists understand leukemia. Beneath the microscope, what looked like disorder turned out to ...
A hidden structure inside the cell is rewriting how scientists understand leukemia. Beneath the microscope, what looked like disorder turned out to ...
A hidden structure inside the cell is rewriting how scientists understand leukemia. Beneath the microscope, what looked like ...
The Chosun Ilbo on MSN
Non-Smoker Lung Cancer Surge, Rycarza Effective for Brain Metastasis
According to the latest statistics from the Ministry of Data and Statistics, 21.9% of cancer-related deaths are attributed to ...
In a world first, a bespoke gene-editing therapy benefited one child. Now researchers plan to launch a clinical trial of the approach ...
Expanded Dose Exploration in Part A and Dose Escalation in Part B of BEAM-302 Phase 1/2 Study in Alpha-1 Antitrypsin Deficiency Ongoing; Updated ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback